ly5

LY5 is an inhibitor of STAT3 that acts by inhibiting cell viability, cell migration, and angiogenesis in medulloblastoma cells.

LY518674 (LY-674) decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα agonist (EC50: 42 nM for human PPARα).

LY550410 is a small molecule that acts as an ATP-competitive type I TGF-β receptor kinase inhibitor (type ITGF-β receptorkinase) featuring a heteroaromatic ring, which can effectively bind to the active site of the kinase domain. This compound regulates the TGF-β signaling pathway, thereby influencing gene expression and ultimately promoting cell growth. LY550410 holds potential for use in cancer research.

Gly5-Ahx-DM1 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. DM1 is a microtubulin inhibitor and can be used in the synthesis of antibody-drug conjugates (ADCs).

LY52 is a matrix metalloproteinase-2 inhibitor. It acts by suppressing tumor invasion and metastasis.

LY503430 is a AMPA receptor potentiator with oral activity. LY503430 has both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP.

LY593093 is a selective partial orthosteric agonist of M1 muscarinic acetylcholine receptor.

PNU-EDA-Gly5 is a DNA topoisomerase I inhibitor-based oligo-glycine linker-payload used for the synthesis of antibody-drug conjugates (ADCs). It consists of the DNA topoisomerase I inhibitor PNU-159682 and the linker EDA-Gly5.